CN115154343A - Composition and preparation for improving eye relaxation and dark circles, preparation method and application - Google Patents
Composition and preparation for improving eye relaxation and dark circles, preparation method and application Download PDFInfo
- Publication number
- CN115154343A CN115154343A CN202211007469.9A CN202211007469A CN115154343A CN 115154343 A CN115154343 A CN 115154343A CN 202211007469 A CN202211007469 A CN 202211007469A CN 115154343 A CN115154343 A CN 115154343A
- Authority
- CN
- China
- Prior art keywords
- skin
- dark circles
- improving
- preparation
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 239000000284 extract Substances 0.000 claims abstract description 49
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 43
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 31
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 28
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960003237 betaine Drugs 0.000 claims abstract description 17
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 16
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims abstract description 16
- 229920000669 heparin Polymers 0.000 claims abstract description 16
- 229960005323 phenoxyethanol Drugs 0.000 claims abstract description 16
- 239000010452 phosphate Substances 0.000 claims abstract description 16
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 15
- 229920000193 polymethacrylate Polymers 0.000 claims abstract description 15
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 14
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 14
- 229960000458 allantoin Drugs 0.000 claims abstract description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 14
- DDADCBXAKYGDEH-UHFFFAOYSA-N 2-(3-hydroxypropyl)oxane-2,3,4-triol Chemical compound OCCCC1(O)OCCC(O)C1O DDADCBXAKYGDEH-UHFFFAOYSA-N 0.000 claims abstract description 12
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 12
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 claims abstract description 11
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 11
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 229960005150 glycerol Drugs 0.000 claims abstract description 8
- 239000000419 plant extract Substances 0.000 claims abstract description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 32
- 238000003756 stirring Methods 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 15
- 239000008367 deionised water Substances 0.000 claims description 14
- 229910021641 deionized water Inorganic materials 0.000 claims description 14
- 239000011668 ascorbic acid Substances 0.000 claims description 13
- 229960005070 ascorbic acid Drugs 0.000 claims description 13
- 235000010323 ascorbic acid Nutrition 0.000 claims description 13
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 claims description 13
- 229940093767 glabridin Drugs 0.000 claims description 13
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 claims description 13
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 12
- 235000013793 astaxanthin Nutrition 0.000 claims description 12
- 239000001168 astaxanthin Substances 0.000 claims description 12
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 12
- 229940022405 astaxanthin Drugs 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 12
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 241001172538 Daemonorops draco Species 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- 241001523681 Dendrobium Species 0.000 claims description 5
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- KOGFZZYPPGQZFZ-QVAPDBTGSA-N (2s,3r,4s,5r)-2-(2-hydroxypropyl)oxane-3,4,5-triol Chemical compound CC(O)C[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O KOGFZZYPPGQZFZ-QVAPDBTGSA-N 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 240000006661 Serenoa repens Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 10
- 102000008186 Collagen Human genes 0.000 abstract description 9
- 108010035532 Collagen Proteins 0.000 abstract description 9
- 229920001436 collagen Polymers 0.000 abstract description 9
- 150000003254 radicals Chemical class 0.000 abstract description 8
- 230000006872 improvement Effects 0.000 abstract description 7
- 230000004089 microcirculation Effects 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 230000000295 complement effect Effects 0.000 abstract description 4
- 210000004177 elastic tissue Anatomy 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 4
- 239000000835 fiber Substances 0.000 abstract description 3
- 230000008021 deposition Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 31
- 230000000052 comparative effect Effects 0.000 description 13
- 201000010251 cutis laxa Diseases 0.000 description 13
- 239000002537 cosmetic Substances 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 235000002673 Dioscorea communis Nutrition 0.000 description 9
- 241000544230 Dioscorea communis Species 0.000 description 9
- 208000035753 Periorbital contusion Diseases 0.000 description 9
- 210000000744 eyelid Anatomy 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 240000004638 Dendrobium nobile Species 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960001008 heparin sodium Drugs 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- -1 alcohol phosphate ester Chemical class 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 101000773110 Pelophylax lessonae Tyrosinase Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000013556 antirust agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QTPILKSJIOLICA-UHFFFAOYSA-N bis[hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(O)=O QTPILKSJIOLICA-UHFFFAOYSA-N 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000013064 chemical raw material Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005536 corrosion prevention Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000009286 sanguis draxonis Substances 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition for improving eye relaxation and dark circles, a preparation method and application, and belongs to the technical field of skin care products. The preparation is prepared from C20-22 alcohol phosphate, allantoin, betaine, glycerol polymethacrylate, sodium hyaluronate, coffee extract, antioxidant, sodium heparin, plant extract, triethanolamine, hydroxypropyl tetrahydropyrane triol, palmitoyl pentapeptide-4, dipotassium glycyrrhizinate, and phenoxyethanol. The raw materials complement and enhance the components, and the efficacy performance is effectively improved. The product can remove free radical dimension to repair and improve skin around eyes; repair and improvement of periocular skin from ocular blood microcirculation and skin metabolism dimensions; repair and improvement of periocular skin from the skin melanin deposition dimension; the skin is tightened by increasing the content dimensions of collagen fibers and elastic fibers in the skin around the eyes, the skin around the eyes is repaired and improved, the problems of eye looseness and dark circles are removed and improved in an all-round mode through four dimensions, the effect is obvious, and the skin is not easy to relapse.
Description
Technical Field
The invention belongs to the technical field of skin care products, and particularly relates to a composition for improving eye laxity and dark circles, a preparation method and application.
Background
Every person needs to blink for tens of thousands of times every day, and the eye skin is continuously extruded and stretched for a long time, so that the skin around the eyes can be quickly loosened.
The thinness of the eye skin is about 1/3 of the thickness of the facial skin, and the subcutaneous tissues are the blood vessels, lymph and other eye tissues. Like over fatigue of eyes, slow metabolism, blood circulation of capillary vessels forming stagnation, insufficient oxygen supply of tissues, and excessive accumulation of waste garbage in blood vessels and skin, the phenomenon is easily shown to form black eyes on the skin.
With the recent increase in social rhythm, lifestyle has also changed. The time for people to contact with electronic products such as televisions, computers, mobile phones and the like is longer and longer, and the eye skin relaxation and the formation of black eyes are easily aggravated when people face overtime work, stay up and boil all night, net play and net lessons for a long time.
Slight loose skin around the eyes and black eye circles can be adjusted along with self work and rest, early sleep can be achieved, the eye time can be shortened, and the eye-care health care product can be slowly relieved. The severe, persistent, periocular laxity and dark circles are difficult to remove once formed without external intervention.
At present, a laser activation method is generally adopted for severe intractable eye skin looseness and dark circles, and the laser mode cannot be accepted by all nations due to the special eye position and certain risk.
There are many related products on the market today, such as: eye cream and eye products with infrared light or blue light have the defects of single function and poor improvement effect.
Disclosure of Invention
The invention aims to provide a preparation capable of improving eye relaxation and dark circles, and the preparation can solve the technical problems of single function, poor improvement effect, risks in operation and the like of products in the prior art.
The invention is realized by the following technical scheme:
a composition for improving eye relaxation and dark circles is prepared from the following raw materials in percentage by mass:
0.2-0.6 wt% of C20-22 alcohol phosphate, 0.1-0.3 wt% of allantoin, 0.5-5 wt% of betaine, 0.5-4 wt% of glycerol polymethacrylate, 0.01-0.1 wt% of sodium hyaluronate, 1-2 wt% of coffee extract, 3.05-8.03 wt% of antioxidant, 0.1-0.2 wt% of sodium heparin, 5-7 wt% of plant extract, 0.2-0.3 wt% of triethanolamine, 2-6 wt% of hydroxypropyl tetrahydropyrane triol, 4-1 wt% of palmitoyl pentapeptide, 0.3-2 wt% of dipotassium glycyrrhizinate, 0.5-1 wt% of phenoxyethanol and the balance of solvent.
Said invention provides a composition for improving relaxed eye and black eye, and said composition uses several complementary synergistic components with reasonable mixing ratio, and can effectively raise the effect performance of said composition.
Wherein the C20-22 alcohol phosphate is used as a surfactant; adding an antioxidant: glabridin, astaxanthin and ascorbic acid have super-strong effects of resisting oxidation, removing free radicals, inhibiting activity of tyrosinase, and effectively inhibiting generation of melanin. The added palm leaf tree extract can greatly promote the blood flow rate around eyes and quickly remove redundant water, toxins and wastes accumulated in eyes. The addition of sodium heparin can improve the dark skin around the eyes due to blood retention. Palmitoyl pentapeptide-4, which has uniquely ordered small molecule pentapeptides, is added to simulate the mechanism of the human body per se to generate collagen through TGF-beta, and simultaneously inhibit MMP (matrix metalloproteinase) to protect the collagen from being degraded. The two ingredients have synergistic effect, so that the effect of tightening the skin is achieved, the plumpness of the eye skin is improved, the eye circumference is tightened, and the eye skin is revived.
Preferably, the plant extract consists of 1wt% -3wt% of daemonorops draco extract, 1wt% -3wt% of palm leaf tree extract and 1wt% -3wt% of dendrobium stem extract.
Preferably, the antioxidant consists of glabridin 0.03-0.05 wt%, astaxanthin 2-5 wt% and ascorbic acid 1-3 wt%.
Preferably, the solvent is deionized water.
The main effects of the raw materials are as follows:
c20-22 alcohol phosphate ester: is anionic surfactant, and can be used as emulsifier in cosmetic.
Glabridin: resisting oxidation, and inhibiting activity of skin tyrosinase.
Ascorbic acid: has effects in resisting oxidation, preventing skin pigmentation, and promoting skin metabolism.
Daemonorops draco extract: improving skin microcirculation and enhancing skin metabolism. Promoting blood circulation and tissue regeneration, relieving pain and inhibiting bacteria, promoting wound healing, etc. Sanguis Draxonis contains tannin, reducing sugar and resin, and has effects of dispelling qi, relieving pain, dispelling pathogenic wind, dredging channels and promoting blood circulation.
Palm leaf extract: improving skin microcirculation and enhancing skin metabolism.
Dendrobium nobile extract: resisting aging, promoting blood circulation for removing blood stasis, and improving skin activity.
Sodium heparin: enhance microcirculation of skin and hair vessels and prevent blood retention.
And (3) coffee extract: accelerating the microcirculation of the skin and relieving edema.
Hydroxypropyl tetrahydropyran triol: promoting the production of skin collagen and preventing skin relaxation.
Palmitoyl pentapeptide-4: promoting skin elastic fiber cells and tightening skin.
Allantoin: is called an anti-irritant and can effectively relieve the irritation of the irritant; meanwhile, the vitamin C is also an antioxidant, and like other water-soluble vitamins, the vitamin C has the same capacity of gathering free radicals as vitamin C, so that the antioxidant capacity of cells can be enhanced. Can combine with a plurality of substances to form compound salt, has the functions of light protection, sterilization, corrosion prevention, pain relief and oxidation resistance, can keep the moisture of the skin, moisten and soften, and is a special additive of cosmetics such as beauty, hairdressing and the like. Has effects in caring skin, keeping moisture, softening cutin, resisting oxidation, and relieving inflammation.
Betaine: also known as trimethylamine ethylene lactone, betanin, and betaine, is a quaternary ammonium derivative of glycine, which is a completely natural, edible amino acid. Betaine mainly has the capability of rapidly improving the moisture retention of skin and hair, has the unique performance of protecting cell membranes by a humectant, and can increase the solubility of active ingredients in water and reduce the irritation of a surfactant or fruit acid to the skin. Betaine also has antiallergic and skin irritation reducing effects.
Glycerin polymethacrylate: can be used as film forming agent and viscosity control agent in cosmetic worker. The glycerin polymethacrylate is a water-soluble transparent gel, is a transparent and multifunctional moisturizing substrate, and can increase skin feel and lubricity and improve moisturizing performance.
Sodium hyaluronate: has better high viscoelasticity, plasticity and permeability and good biocompatibility. It has been widely used in the production of cosmetics as a natural moisturizer.
Triethanolamine: TEOA, also known as TEOA, TEA. The alias is 2, 2-hydroxy triethylamine, trihydroxyethylamine, and the chemical formula (molecular formula) C 6 H 15 O 3 N is colorless to light yellow viscous liquid with ammonia smell, is easily dissolved in water and ethanol, is alkaline, has the pH value of the aqueous solution of about 10.5, is a chemical raw material with wide application, and is used as a vulcanization active agent of non-carbon black reinforced rubber materials, an emulsifying agent of oils and waxes, a metal cutting cooling agent, an antirust agent, a cement early strength agent, a neutralizing agent, an acid gas absorbent, a daily chemical product wetting agent and the like. It also has neutralizing effect in cosmetic, and can neutralize CP-940 to achieve thickening and moisturizing effects.
Dipotassium glycyrrhizinate: is white or quasi-white fine powder, has purity up to 98%, special sweet taste, good water solubility and pure taste. Dipotassium glycyrrhizinate has multiple effects of bacteriostasis, inflammation diminishing, detoxification, anti-allergy, deodorization and the like. The method can be widely applied to the industries of medicine, cosmetics, daily chemicals, food and the like. Can be used in eye drop and stomatitis. The corticosteroid can be activated (inhibiting metabolic enzymes). The effect of the corticosteroid compound is indirectly enhanced, the corticosteroid compound can be used for all cosmetics such as cream, water, emulsion, milk, honey and the like, can neutralize or reduce toxic substances of the cosmetics, can also prevent the anaphylactic reaction of some cosmetics, and is more suitable for high-grade hair or used in the cosmetics, and the market specification is that UV is more than or equal to 98 percent and HPLC is more than or equal to 76 percent (referring to the effective component of glycyrrhizic acid). The cosmetic has wide compatibility, can be frequently used together with other active agents, can accelerate the absorption of the skin to the active agents to enhance the effect, and can be used for sun protection, assisting whitening, relieving itching, regulating sebum, growing hair and protecting hair and the like. Can be used for preventing dermatitis, xerosis cutis, sunburn, erythra, and throat moistening. Spot-removing agent, and antiallergic agent. Can be used for resisting allergy, preventing sunburn, caring skin lotion, and removing speckle cream and lotion.
Phenoxyethanol: is an organic compound frequently used in skin care products, can be prepared by etherification of ethylene glycol and phenol, and is commonly used in skin care creams and sunscreen creams. Phenoxyethanol is a colorless oily liquid with antibacterial efficacy (commonly used with quaternary ammonium salts), and is often used as a highly toxic substitute for sodium azide in biolofibre solutions because 2-phenoxyethanol is less toxic and chemically inert to copper and lead. It is commonly used as a preservative in cosmetics, skin care products, vaccines and pharmaceuticals.
A preparation for improving eye laxity and dark circles is prepared from the composition for improving eye laxity and dark circles.
A method for preparing a preparation for improving eye laxity and dark circles, which comprises the following steps:
selecting triethanolamine and sodium hyaluronate according to corresponding mass fractions, and dispersing in a solvent accounting for 2-3wt% of the total mass of the preparation to obtain a material A;
selecting C20-22 alcohol phosphate, allantoin, betaine, glycerol polymethacrylate and the rest solvent according to corresponding mass fractions, uniformly mixing, heating and stirring, cooling to 50-60 ℃, adding the material A, stirring, cooling to 40-45 ℃, adding a coffee extract, an antioxidant, a plant extract, sodium heparin, hydroxypropyl tetrahydropyrane triol, palmitoyl pentapeptide-4, dipotassium glycyrrhizinate and phenoxyethanol, and uniformly mixing.
Preferably, in the heating and stirring step, the heating temperature is 85 to 90 ℃.
Preferably, in the heating and stirring step, the stirring time is 10-25min.
Preferably, in the heating and stirring step, the time for adding the material A and stirring is 10-15min.
An application of a preparation for improving eye laxity and dark circles in preparing products for tightening the eye periphery and removing the dark circles.
Compared with the prior art, the invention at least has the following technical effects:
the invention provides a composition for improving eye relaxation and dark circles, which effectively improves the efficacy performance of the composition by using various complementary synergistic components with reasonable mixture ratio.
Wherein, the C20-22 alcohol phosphate is used as a surfactant; adding an antioxidant: glabridin, astaxanthin and ascorbic acid have super strong antioxidation, free radical eliminating effect, activity of tyrosinase inhibiting, and melanin generation inhibiting effects. The added palm leaf tree extract can greatly promote the blood flow rate around eyes and quickly remove redundant water, toxins and wastes accumulated in eyes. The addition of sodium heparin can improve the dark skin around the eyes due to blood retention. Palmitoyl pentapeptide-4 which has uniquely ordered small molecule pentapeptide is added to simulate the mechanism of human body to generate collagen through TGF-beta, and simultaneously inhibit MMP (matrix metalloproteinase) to protect the collagen from being degraded. The two ingredients have synergistic effect, so that the effect of tightening the skin is achieved, the plumpness of the eye skin is improved, the eye circumference is tightened, and the eye skin is revived.
The product can remove and improve the problems of loose eyes and dark circles in all directions from four dimensions. Firstly, because a large amount of peroxide free radicals are generated on the electronic product and eye skin in a long-time overload way, the free radicals influence the normal self-repair of the eye skin, and the eye skin is repaired and improved from the dimension of removing the free radicals; secondly, the repair and improvement of the skin around the eyes are carried out from the dimension of blood microcirculation and skin metabolism of the eyes; thirdly, repairing and improving the skin around the eyes from the dimension of skin melanin deposition; fourthly, the dimension of increasing the content of collagen fibers and elastic fibers in the skin around the eyes is used for tightening the skin and repairing and improving the skin around the eyes.
And (III) the product of the application is a preferable efficacy combination and supplements the effects of the product to thoroughly improve the problems of loose eye skin and dark circles.
And (IV) the product effectively improves the efficacy performance of the composition through multiple complementary synergistic components with reasonable mixture ratio. Has obvious effects of tightening skin around eyes and removing dark eye circles, and is not easy to relapse after being decocted all the time.
Drawings
FIG. 1 is a graph showing the results of comparison before and after treatment of patient 1 using the product prepared in example 3;
FIG. 2 is a graph showing the results of comparison before and after treatment of patient 2 using the product prepared in example 3;
FIG. 3 is a graph showing the results of comparison before and after treatment of patient 3 using the product prepared in example 3;
FIG. 4 is a graph showing comparative results before and after treatment of patient 4 using the product prepared in example 3;
FIG. 5 is a graph showing the results of comparison before and after treatment of patient 5 using the product prepared in example 3;
FIG. 6 is a graph showing comparative results before and after treatment of patient 6 using the product prepared in example 3;
FIG. 7 is a graph showing the results of comparison before and after treatment of patient 7 using the product prepared in example 3;
FIG. 8 is a graph showing the results of comparison before and after treatment of patient 8 using the product prepared in example 3;
FIG. 9 is a graph showing the results of comparison before and after treatment of patient 9 using the product prepared in example 3;
FIG. 10 is a graph showing comparative results before and after treatment of patient 10 using the product prepared in example 3;
FIG. 11 is a graph showing comparative results before and after treatment of patient 11 using the product prepared in example 3;
FIG. 12 is a graph comparing results before and after treatment for patient 12 using the product prepared in example 3.
Detailed Description
Embodiments of the present invention will be described in detail with reference to the following examples, but those skilled in the art will understand that the following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the present invention, and that the specific conditions not specified in the examples are carried out according to conventional conditions or conditions suggested by the manufacturer, and that the reagents or equipment used are not specified by the manufacturer, and are all conventional products available through commercial purchase.
The technical scheme of the invention is as follows:
a composition for improving eye relaxation and dark circles is prepared from the following raw materials in parts by mass: 0.2 to 0.6 weight percent of 20 to 22 alcohol phosphate, 0.1 to 0.3 weight percent of allantoin, 0.5 to 5 weight percent of betaine, 0.5 to 4 weight percent of glycerol polymethacrylate, 0.01 to 0.1 weight percent of sodium hyaluronate, 1 to 2 weight percent of coffee extract, 0.03 to 0.05 weight percent of glabridin, 0.1 to 0.2 weight percent of sodium heparin, 1 to 3 weight percent of sanguis draconis extract, 0.2 to 0.3 weight percent of triethanolamine, 2 to 5 weight percent of astaxanthin, 2 to 6 weight percent of hydroxypropyl tetrahydropyrane triol, 1 to 4 weight percent of palmitoyl pentapeptide, 1 to 3 weight percent of palm leaf extract, 1 to 3 weight percent of dendrobium nobile extract, 1 to 3 weight percent of ascorbic acid, 0.3 to 2 weight percent of dipotassium glycyrrhizinate, 0.5 to 1 weight percent of phenoxyethanol and the balance of deionized water.
A preparation for improving eye laxity and dark circles is prepared from the composition for improving eye laxity and dark circles.
A preparation method of a preparation for improving eye laxity and dark circles comprises the following steps;
pre-dispersing triethanolamine, sodium hyaluronate and deionized water accounting for 2wt% of the total weight of the preparation to obtain a material A;
mixing C20-22 alcohol phosphate, allantoin, betaine, glycerol polymethacrylate and the rest deionized water, stirring and heating to 85-90 ℃, keeping the temperature and stirring for 10-25min, cooling to 50-60 ℃, adding the material A, keeping the temperature and stirring for 10-15min, cooling to 45 ℃, adding coffee extract, glabridin, heparin sodium, daemonorops draco extract, astaxanthin, hydroxypropyl tetrahydropyrane triol, palmitoyl pentapeptide-4, palm leaf tree extract, dendrobium nobile extract, ascorbic acid, dipotassium glycyrrhizate, phenoxyethanol, and uniformly stirring to obtain the preparation for improving loose eyes and black eye circles.
Example 1
A composition for improving eye relaxation and dark circles is prepared from the following raw materials in percentage by mass: 0.2wt% of c20-22 alcohol phosphate, 0.1wt% of allantoin, 0.5wt% of betaine, 4wt% of glycerol polymethacrylate, 0.1wt% of sodium hyaluronate, 1wt% of coffee extract, 0.03wt% of glabridin, 0.2wt% of sodium heparin, 1wt% of daemonorops draco extract, 0.2wt% of triethanolamine, 5wt% of astaxanthin, 2wt% of hydroxypropyl tetrahydropyrane triol, 4 1wt% of palmitoyl pentapeptide, 1wt% of palm leaf tree extract, 1wt% of dendrobium stem extract, 3wt% of ascorbic acid, 0.3wt% of dipotassium glycyrrhizinate, 1wt% of phenoxyethanol and the balance of deionized water to 100wt%.
A preparation for improving slack eyes and dark circles is prepared from the composition for improving the slack eyes and the dark circles.
A preparation method of a preparation for improving eye laxity and dark circles comprises the following steps;
pre-dispersing triethanolamine, sodium hyaluronate and deionized water accounting for 2wt% of the total weight of the preparation to obtain a material A;
mixing C20-22 alcohol phosphate, allantoin, betaine, glycerol polymethacrylate and the rest deionized water, stirring and heating to 85 ℃, keeping the temperature and stirring for 25min, cooling to 60 ℃, adding the material A, keeping the temperature and stirring for 10min, cooling to 45 ℃, adding coffee extract, glabridin, heparin sodium, daemonorops draco extract, astaxanthin, hydroxypropyl tetrahydropyrane triol, palmitoyl pentapeptide-4, palm leaf tree extract, dendrobium nobile extract, ascorbic acid, dipotassium glycyrrhetate and phenoxyethanol, and stirring uniformly to obtain the preparation for improving eye relaxation and black eye circles.
Example 2
A composition for improving eye relaxation and dark circles is prepared from the following raw materials in parts by mass: 0.6wt% of c20-22 alcohol phosphate, 0.3wt% of allantoin, 5wt% of betaine, 0.5wt% of glycerol polymethacrylate, 0.01wt% of sodium hyaluronate, 2wt% of coffee extract, 0.05wt% of glabridin, 0.1wt% of sodium heparin, 3wt% of daemonorops draco extract, 0.3wt% of triethanolamine, 2wt% of astaxanthin, 6wt% of hydroxypropyl tetrahydropyrane triol, 4wt% of palmitoyl pentapeptide, 3wt% of palm leaf tree extract, 3wt% of dendrobium stem extract, 1wt% of ascorbic acid, 2wt% of dipotassium glycyrrhizinate, 0.5wt% of phenoxyethanol, and the balance of deionized water to 100wt%.
A preparation for improving eye laxity and dark circles is prepared from the composition for improving eye laxity and dark circles.
A preparation method of a preparation for improving eye laxity and dark circles comprises the following steps;
pre-dispersing triethanolamine, sodium hyaluronate and deionized water accounting for 3wt% of the total weight of the preparation to obtain a material A;
mixing C20-22 alcohol phosphate, allantoin, betaine, glycerol polymethacrylate and the rest deionized water, stirring and heating to 90 ℃, keeping the temperature and stirring for 10min, cooling to 50 ℃, adding the material A, keeping the temperature and stirring for 15min, cooling to 45 ℃, adding coffee extract, glabridin, heparin sodium, daemonorops draco extract, astaxanthin, hydroxypropyl tetrahydropyrane triol, palmitoyl pentapeptide-4, palm leaf tree extract, dendrobium nobile extract, ascorbic acid, dipotassium glycyrrhetate and phenoxyethanol, and stirring uniformly to obtain the preparation for improving eye relaxation and black eye circles.
Example 3
A composition for improving eye relaxation and dark circles is prepared from the following raw materials in percentage by mass: c20-22 alcohol phosphate 0.5wt%, allantoin 0.2wt%, betaine 0.3wt%, glycerol polymethacrylate 3wt%, sodium hyaluronate 0.1wt%, coffee extract 2wt%, glabridin 0.05wt%, sodium heparin 0.2wt%, daemonorops draco extract 3wt%, triethanolamine 0.2wt%, astaxanthin 5wt%, hydroxypropyl tetrahydropyrane triol 5wt%, palmitoyl pentapeptide-4 3wt%, palm leaf tree extract 3wt%, dendrobium stem extract 3wt%, ascorbic acid 3wt%, dipotassium glycyrrhizinate 0.3wt%, phenoxyethanol 0.5wt%, and the balance of deionized water to 100wt%.
A preparation for improving eye laxity and dark circles is prepared from the composition for improving eye laxity and dark circles.
A preparation method of a preparation for improving eye laxity and dark circles comprises the following steps;
pre-dispersing triethanolamine, sodium hyaluronate and deionized water accounting for 2wt% of the total weight of the preparation to obtain a material A;
mixing C20-22 alcohol phosphate, allantoin, betaine, glycerol polymethacrylate and the rest deionized water, stirring and heating to 85-90 ℃, keeping the temperature and stirring for 10-25min, cooling to 50-60 ℃, adding the material A, keeping the temperature and stirring for 10-15min, cooling to 45 ℃, adding coffee extract, glabridin, heparin sodium, dawn extract, astaxanthin, hydroxypropyl tetrahydropyrane triol, palmitoyl pentapeptide-4, palm leaf tree extract, dendrobium nobile extract, ascorbic acid, dipotassium glycyrrhetate and phenoxyethanol, and stirring uniformly to obtain the preparation for improving the loose eyes and black eye circles.
And (3) experimental comparison:
example 3 was used as an experimental example, and the following 3 comparative examples were designed and compared.
The preparation of 3 comparative examples was the same as that of example 3.
The specific experimental and comparative example raw materials used are as follows:
the first test: evaluation of skin firming Effect
The deep cause of skin relaxation is the decrease in the activity of fibroblasts, and the decrease in the secretion of collagen and elastin, which leads to sagging and sagging of the skin.
This experiment was used to evaluate the effect of the formulation prepared from the composition on fibroblast proliferation.
The ability to tighten the skin can be evaluated to some extent, and the proliferation of fibroblasts can be detected by the MTT method.
The test operation method is as follows:
fibroblast cells (RAB-iCell-s 010, saiboubangui), were digested with 0.25% trypsin and cell suspension concentration was adjusted to 120/ml, and inoculated uniformly into 48-well plates, 100. Mu.l was added dropwise to each well, and the marginal wells were filled with a pentaphosphate buffer. After culturing in a C20 incubator for 24 hours, the culture supernatant was aspirated, 100. Mu.l of a medium (bovine serum) diluent containing 50% of the sample was added to each well, and 8 duplicate wells were provided for each of the four samples of Experimental example, comparative example 1, comparative example 2, and comparative example 3, and a blank control group without the added sample was provided. After culturing for 48 hours, respectively, sucking out the culture supernatant, adding 100 mu l of DMEM culture solution into each well, adding 5mg/ml of MTT solution, culturing for 4 hours in a C02 incubator, carefully sucking out the culture supernatant, adding 150 mu l of DMSO into each well, shaking on a shaker for 15min to dissolve crystals, and measuring the absorbance (A) value at 490nm by using an enzyme-linked immunosorbent assay.
The test results are shown in table 1 below.
TABLE 1 Effect of various compositions on skin fibroblast growth
The above can be seen from table 1: the skin-tightening composition in the experimental example has the effect of obviously promoting the proliferation of skin fibroblasts, namely has the functions of tightening skin and removing wrinkles.
And (2) testing II: and (3) evaluation of black eye removal effect:
in order to verify that the preparation has the effects of tightening skin and removing dark circles.
30 volunteers (aged 40-50 years with dark circles and similar degree of skin laxity around the eyes) were randomly assigned to 2 groups of 15 people each.
The test operation method comprises the following steps:
the product (group one is a comparative example: skin lotion without specific efficacy, experimental example for group two) is used 2 times per day around eyes, 0.8g (eyes) is used once, the product is continuously used for four weeks, the change degree of the eye skin is observed every week, the product is stopped for 4 weeks, and the change degree of the eye skin is observed every week.
TABLE 2 comparative test results (group one)
TABLE 3 Experimental examples test results (group two)
The results of the above tables 2 and 3 show that: the use effect comparison of volunteers on the experimental examples and the comparative examples proves that the experimental examples can achieve the effects of removing black eye circles and tightening eye skins through the advantage combination of the effective components.
The preparation protected by the application starts with the dimensionalities of removing free radicals, inhibiting melanin sedimentation and the microcirculation environment of eye skin, and the content of collagen fibers and elastic fibers in skin, and the like, can fundamentally solve the problems of eye skin looseness and black eye circles, does not solve the surface phenomenon, and can achieve the effect of treating both symptoms and root causes.
Clinical cases:
patient 1: liu Jie, age 48 years old, loose skin on the lower eyelid. Symptoms disappeared after 3,3 months using this example.
Patient 2: ma Shi, age 43 years old, with loose skin on the lower eyelid, and mild dark circles. Using this example 3,2 half-months of symptoms disappeared.
Patient 3: liu Jie, age 63 years old, loose skin around eyes. The improvement effect of the skin laxity around the eyes was remarkable after 3,3 months using this example.
Patient 4: ding, age 38 years old, loose skin of the lower eyelid, and slight dark circles. Using this example, symptoms disappeared in 3,3 months.
Patient 5: wangzhi, age 32 years old, with loose skin on the lower eyelid. Using this example, 3,3 months, symptoms disappeared.
Patient 6: old, age 33 years, loose skin of the lower eyelid. Using this example, 3,3 months, symptoms disappeared.
Patient 7: lie, age 34 years, with loose skin on the lower eyelid. Using this example for 3,3 months, the symptoms disappeared.
Patient 8: wangzhi, age 36 years old, with loose skin on the lower eyelid. Using this example for 3,3 months, the symptoms disappeared.
Patient 9: thanks to certain age, 37 years old, severe dark circles under the eyes, loose skin of the lower eyelid. Using this example, 3,2 months, symptoms disappeared.
The patient 10: zhangzhi, age 41 years old, severe dark circles under the eyes, mild laxity of the skin of the lower eyelid. Using this example 2 for half a month, the symptoms disappeared.
Patient 11: liu Jie, the age of 43 years old, severe dark under-eye circles and loose skin in the lower eyes. Using this example, symptoms disappeared in 3,3 months.
Patient 12: li Shi, age 23 years old, moderate dark circles. With this example 3,1 month the symptoms disappeared.
The cases 1-8 are mainly used for treating eye bags; cases 9-12 are mainly treated for dark circles.
Finally, it should be noted that: the above description is only a preferred embodiment of the present invention, and is not intended to limit the scope of the present invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. The composition for improving the relaxation and the dark circles of the eyes is characterized by being prepared from the following raw materials in percentage by mass:
0.2-0.6 wt% of C20-22 alcohol phosphate, 0.1-0.3 wt% of allantoin, 0.5-5 wt% of betaine, 0.5-4 wt% of glycerol polymethacrylate, 0.01-0.1 wt% of sodium hyaluronate, 1-2 wt% of coffee extract, 3.05-8.03 wt% of antioxidant, 0.1-0.2 wt% of sodium heparin, 5-7 wt% of plant extract, 0.2-0.3 wt% of triethanolamine, 2-6 wt% of hydroxypropyl tetrahydropyran triol, 4-1 wt% of palmitoyl pentapeptide, 0.3-2 wt% of dipotassium glycyrrhizinate, 0.5-1 wt% of phenoxyethanol and the balance of solvent.
2. The composition for improving laxity of the eyes and dark circles as claimed in claim 1, wherein the plant extract comprises 1wt% -3wt% of daemonorops draco extract, 1wt% -3wt% of palmetto tree extract and 1wt% -3wt% of dendrobium stem extract.
3. The composition for improving laxity and dark circles around eyes as claimed in claim 1, wherein the antioxidant is composed of glabridin 0.03wt% -0.05wt%, astaxanthin 2wt% -5wt% and ascorbic acid 1wt% -3 wt%.
4. The composition for improving relaxed eye and dark circles as claimed in claim 1, wherein the solvent is deionized water.
5. A preparation for improving eye laxity and dark circles, which is prepared from the composition for improving eye laxity and dark circles as claimed in any one of claims 1 to 4.
6. A method of preparing the formulation for improving ocular laxity and dark circles of claim 5, comprising:
selecting triethanolamine and sodium hyaluronate according to corresponding mass fractions, and dispersing in a solvent accounting for 2-3wt% of the total mass of the preparation to obtain a material A;
selecting C20-22 alcohol phosphate, allantoin, betaine, glycerol polymethacrylate and the rest solvent according to corresponding mass fractions, uniformly mixing, heating and stirring, cooling to 50-60 ℃, adding the material A, stirring, cooling to 40-45 ℃, adding a coffee extract, an antioxidant, a plant extract, sodium heparin, hydroxypropyl tetrahydropyrane triol, palmitoyl pentapeptide-4, dipotassium glycyrrhizinate and phenoxyethanol, and uniformly mixing.
7. The method for preparing a preparation for improving laxity and dark circles around eyes according to claim 6, wherein in the step of heating and stirring, the temperature is increased to 85-90 ℃.
8. The method for preparing the preparation for improving the laxity of the eyes and the dark circles according to claim 7, wherein in the step of heating and stirring, the stirring time is 10-25min.
9. The method for preparing the preparation for improving the laxity of the eyes and the dark circles according to claim 6, wherein in the step of heating and stirring, the material A is added and stirred for 10-15min.
10. Use of the preparation for improving eye laxity and dark circles according to claim 5 for preparing a product for tightening the eye periphery and removing dark circles.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211007469.9A CN115154343B (en) | 2022-08-22 | 2022-08-22 | Composition and preparation for improving eye relaxation and black eye, preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211007469.9A CN115154343B (en) | 2022-08-22 | 2022-08-22 | Composition and preparation for improving eye relaxation and black eye, preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115154343A true CN115154343A (en) | 2022-10-11 |
CN115154343B CN115154343B (en) | 2024-06-25 |
Family
ID=83481223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211007469.9A Active CN115154343B (en) | 2022-08-22 | 2022-08-22 | Composition and preparation for improving eye relaxation and black eye, preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115154343B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117838597A (en) * | 2024-01-10 | 2024-04-09 | 中南大学湘雅二医院 | Composition for improving eye microcirculation and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105687055A (en) * | 2016-03-23 | 2016-06-22 | 广东芭薇生物科技股份有限公司 | Eye repair essence and preparation method thereof |
CN113679646A (en) * | 2021-08-09 | 2021-11-23 | 深圳市护家科技有限公司 | Caffeine firming and repairing eye cream and preparation method thereof |
-
2022
- 2022-08-22 CN CN202211007469.9A patent/CN115154343B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105687055A (en) * | 2016-03-23 | 2016-06-22 | 广东芭薇生物科技股份有限公司 | Eye repair essence and preparation method thereof |
CN113679646A (en) * | 2021-08-09 | 2021-11-23 | 深圳市护家科技有限公司 | Caffeine firming and repairing eye cream and preparation method thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117838597A (en) * | 2024-01-10 | 2024-04-09 | 中南大学湘雅二医院 | Composition for improving eye microcirculation and application thereof |
CN117838597B (en) * | 2024-01-10 | 2024-08-30 | 中南大学湘雅二医院 | Composition for improving eye microcirculation and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN115154343B (en) | 2024-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107595724B (en) | Skin matrix and preparation method thereof and the cosmetics including it | |
CN107334726B (en) | Acne-removing composition and preparation method and application thereof | |
CN110664716A (en) | Emulsifying system and application thereof, active composition and application thereof, cosmetic and preparation method | |
CN110123695B (en) | Cell energy restoration composition | |
EP1140006B1 (en) | Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis | |
CN109998937B (en) | Cosmetic series containing glycerol glucoside (alpha GG) and preparation method thereof | |
CN107174560B (en) | Mild moisturizing and relieving cleansing water and preparation method thereof | |
CN110051602B (en) | Skin moistening, moisturizing and repairing emulsion and preparation method thereof | |
CN105456140A (en) | Sprout composition and preparation method thereof | |
KR102475897B1 (en) | Mask cosmetic composition comprising Graviola antibiotic extract and method of preparing the same | |
KR20120056594A (en) | Cosmetic composition containing SARGASSUM FULVELLUM extract, CODIUM FRAGILE extract and UNDARIA PINNATIFIDA extract | |
CN114712275A (en) | Anti-wrinkle repair composition and preparation method thereof, and cosmetic and preparation method thereof | |
CN115154343B (en) | Composition and preparation for improving eye relaxation and black eye, preparation method and application | |
KR102220534B1 (en) | Soothing cream and manufacturing method for the same | |
KR101822092B1 (en) | Cosmetic composition for preventing thermal skin aging containing aloe vera leaves complex extract | |
CN107837223B (en) | Facial mask essence containing dendrobium officinale extract, facial mask containing dendrobium officinale extract, preparation method of facial mask essence and application of facial mask essence | |
CN109875944A (en) | A kind of facial mask liquid and preparation method thereof | |
CN111991316A (en) | Anti-allergy repairing composition and preparation method and application thereof | |
KR102381645B1 (en) | Cosmetic Composition Comprising Poria cocos Fermentation Extract | |
KR102108116B1 (en) | A cosmetic composition comprising a natural component and an oil component | |
CN114469817B (en) | Pore-shrinking composition and preparation method and application thereof | |
KR101876744B1 (en) | A step 3 method for improving skin condition using cosmetic composition comprising a ginseng extract | |
KR102475898B1 (en) | Cosmetic composition comprising Graviola antibiotic extract and method of preparing the same | |
CN112451402A (en) | Repairing and moisturizing mask liquid, mask and application thereof | |
CN112656742A (en) | Grape seed red wine mask paste and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |